Variations in the treatment of rheumatoid arthritis in Spain

被引:14
作者
González-Alvaro, I
Hernández-García, C
García, VV
Vargas, E
Ortiz, AM
机构
[1] Univ Madrid, Hosp La Princesa, Serv Reumatol, Madrid 28006, Spain
[2] Univ Madrid, Hosp La Paz, Madrid 3, Spain
[3] Univ Madrid, Hosp Clin San Carlos, Serv Reumatol, Madrid 3, Spain
[4] Univ Madrid, Hosp Clin San Carlos, Serv Farmacol Clin, Madrid 3, Spain
来源
MEDICINA CLINICA | 2002年 / 118卷 / 20期
关键词
rheumatoid arthritis; treatment; drugs; Spain;
D O I
10.1016/S0025-7753(02)72526-8
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
BACKGROUND: Variations in the use of healthcare resources can result in differences in the outcome of rheumatoid arthritis (RA). The emAR study was developed to determine variations in. the management of socio-sanitary resources, including drugs use, in patients with this disorder. PATIENTS AND METHOD: The clinical records of 1,379 patients, randomly selected among all RA patients attended in Spanish hospitals, were reviewed. Information about prescription of disease modifying anti-rheumatic drugs (DMARD), non-steroidal anti-inflammatory drugs (NSAID), corticosteroids, analgesics, gastric protectors and drugs for osteoporosis was collected. In addition, socio-demographic- and disease-related information, as well as data from hospitals, medical units and responsible physicians were also obtained in each patient. RESULTS: There was a high level of DMARD and NSAID prescription that was associated with patient or disease characteristics. Treatment with corticosteroids, as well as with the remaining drugs, showed a substantial regional variability, which may be related to physician-associated variables as well as to patient- and disease-associated characteristics. CONCLUSIONS: Variability in the management of therapeutic resources in RA patients mainly depends on the characteristics of the patient or the disease. There is also a variation that is influenced by physician's characteristics; in some cases, the available scientific evidence may not support this variability.
引用
收藏
页码:771 / 776
页数:6
相关论文
共 39 条
[1]
Abu-Shakra M, 1998, ARTHRITIS RHEUM, V41, P1190, DOI 10.1002/1529-0131(199807)41:7<1190::AID-ART7>3.0.CO
[2]
2-B
[3]
ALARCON GS, 1995, RHEUM DIS CLIN N AM, V21, P589
[4]
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis [J].
Albers, JMC ;
Paimela, L ;
Kurki, P ;
Eberhardt, KB ;
Emery, P ;
van't Hof, MA ;
Schreuder, FHJM ;
Leirisalo-Repo, M ;
van Riel, PLCM .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (05) :453-458
[5]
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[6]
2-9
[7]
Bérard A, 2000, J RHEUMATOL, V27, P1648
[8]
Bergström U, 1999, SCAND J RHEUMATOL, V28, P160
[9]
Choi HK, 2000, ARTHRITIS RHEUM, V43, P2316, DOI 10.1002/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO
[10]
2-6